Where Biology, AI and Clinical Reality Meet

I have been building AI-driven, multi-omics discovery platforms since before it was a category (2009), and advancing them into the clinic. Now I help founders, pharma R&D leaders, and investors tell which platforms actually work, and turn the ones that do into fundable, clinically credible assets.

Founding-team architect of one of the earliest integrated multi-omics + Bayesian AI drug-discovery platforms: >75% in-silico-to-in-vitro validation, 80% lower discovery cost, timelines cut from 36 to 18 months.

• 6  — first-in-class programs advanced towards clinical stage

• 2  — FDA Orphan Drug Designations secured

• $33M+  — in dilutive & non-dilutive capital enabled

• >75%  — in-silico-to-in-vitro validation on the platform I built

• 150+  — person R&D organizations built and led

• 59  — peer-reviewed publications; multiple granted patents